Table 2 GAP stage in patients with IPF at initiations of antifibrotic therapy.

From: Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis

 

IPF combined cohort (n = 229)

Hamamatsu cohort (n = 110)

Seirei cohort (n = 119)

p-value (Hamamatsu cohort vs Seirei cohort)

Stage I

91 (39.7%)

42 (38.2%)

49 (41.2%)

0.6862

Stage II

108 (47.2%)

48 (43.6%)

60 (50.4%)

0.3540

Stage III

30 (13.1%)

20 (18.2%)

10 (8.4%)

0.0321

  1. GAP Gender-Age-Physiology.
Back to article page